TY - JOUR
T1 - Neuroinflammation
T2 - A Modifiable Pathway Linking Obesity, Alzheimer's disease, and Depression
AU - Ly, Maria
AU - Yu, Gary Z.
AU - Mian, Ali
AU - Cramer, Austin
AU - Meysami, Somayeh
AU - Merrill, David A.
AU - Samara, Amjad
AU - Eisenstein, Sarah A.
AU - Hershey, Tamara
AU - Babulal, Ganesh M.
AU - Lenze, Eric J.
AU - Morris, John C.
AU - Benzinger, Tammie L.S.
AU - Raji, Cyrus A.
N1 - Publisher Copyright:
© 2023 American Association for Geriatric Psychiatry
PY - 2023/10
Y1 - 2023/10
N2 - Obesity, depression and Alzheimer's disease (AD) are three major interrelated modern health conditions with complex relationships. Early-life depression may serve as a risk factor for AD, while late-life depression may be a prodrome of AD. Depression affects approximately 23% of obese individuals, and depression itself raises the risk of obesity by 37%. Mid-life obesity independently increases AD risk, while late-life obesity, particularly metabolically healthy obesity, may offer protection against AD pathology. Chronic inflammation serves as a key mechanism linking obesity, AD, and depression, encompassing systemic inflammation from metabolic disturbances, immune dysregulation through the gut microbiome, and direct interactions with amyloid pathology and neuroinflammation. In this review, we explore the biological mechanisms of neuroinflammation in relation to obesity, AD, and depression. We assess the efficacy of therapeutic interventions targeting neuroinflammation and discuss current and future radiological imaging initiatives for studying neuroinflammation. By comprehending the intricate interplay among depression, obesity, and AD, especially the role of neuroinflammation, we can advance our understanding and develop innovative strategies for prevention and treatment.
AB - Obesity, depression and Alzheimer's disease (AD) are three major interrelated modern health conditions with complex relationships. Early-life depression may serve as a risk factor for AD, while late-life depression may be a prodrome of AD. Depression affects approximately 23% of obese individuals, and depression itself raises the risk of obesity by 37%. Mid-life obesity independently increases AD risk, while late-life obesity, particularly metabolically healthy obesity, may offer protection against AD pathology. Chronic inflammation serves as a key mechanism linking obesity, AD, and depression, encompassing systemic inflammation from metabolic disturbances, immune dysregulation through the gut microbiome, and direct interactions with amyloid pathology and neuroinflammation. In this review, we explore the biological mechanisms of neuroinflammation in relation to obesity, AD, and depression. We assess the efficacy of therapeutic interventions targeting neuroinflammation and discuss current and future radiological imaging initiatives for studying neuroinflammation. By comprehending the intricate interplay among depression, obesity, and AD, especially the role of neuroinflammation, we can advance our understanding and develop innovative strategies for prevention and treatment.
KW - Alzheimer's disease
KW - Neuroinflammation
KW - depression
KW - neuroimaging
KW - obesity
UR - http://www.scopus.com/inward/record.url?scp=85163279435&partnerID=8YFLogxK
U2 - 10.1016/j.jagp.2023.06.001
DO - 10.1016/j.jagp.2023.06.001
M3 - Review article
C2 - 37365110
AN - SCOPUS:85163279435
SN - 1064-7481
VL - 31
SP - 853
EP - 866
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 10
ER -